AI-to-Value Board Scorecard for Pharma Supply Chain
In this episode of Center of Excellence - Pharma 4.0, we explore how pharmaceutical companies can move beyond AI experimentation and prove tangible business and patient value across the supply chain.
The discussion examines the AI-to-Value Board Scorecard, a structured framework that connects AI investments to measurable outcomes—from operational excellence and financial performance to patient-centric outcomes.
Key Topics Covered
How AI can predict supply chain disruptions before they impact medicine availability
AI applications in demand forecasting, shortage prediction, supplier risk intelligence, cold-chain monitoring, and serialization
Why workforce adoption and “decisions augmented” are critical to realizing AI value
Connecting AI initiatives to cycle time, inventory, forecast accuracy, OTIF, working capital, ROI, and payback
Why patient centricity must remain the ultimate measure of AI success
The importance of data integrity, cybersecurity, model drift, explainability, human oversight, and GxP validation
How boards can evaluate AI initiatives through four decisions: Scale, Improve, Hold, or Stop
Understanding the AI contribution equation: Financial Value + Risk Avoided + Patient Value − Lifecycle Cost
Why pharmaceutical companies must measure outcomes, not model accuracy alone
The Big Takeaway
AI value in pharma does not come from having the most sophisticated algorithm. It comes from creating a governed, measurable chain of value that ultimately improves medicine availability, product integrity, supply resilience, business performance, and patient outcomes.
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr. Jayant Joshi. Innehållet i podden är skapat av Dr. Jayant Joshi och inte av,
eller tillsammans med, Poddtoppen.
